Nanexa AB (publ) (STO:NANEXA)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.980
-0.030 (-0.75%)
Mar 5, 2026, 3:04 PM CET
192.65%
Market Cap 659.99M
Revenue (ttm) 55.94M
Net Income (ttm) -11.39M
Shares Out 164.59M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 199,313
Average Volume 624,875
Open 4.005
Previous Close 4.010
Day's Range 3.915 - 4.005
52-Week Range 0.701 - 5.000
Beta 2.00
RSI 60.45
Earnings Date Feb 19, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ... [Read more]

Sector Healthcare
Founded 2007
Employees 15
Stock Exchange Nasdaq Stockholm
Ticker Symbol NANEXA
Full Company Profile

Financial Performance

In 2025, Nanexa AB's revenue was 55.94 million, an increase of 19.80% compared to the previous year's 46.69 million. Losses were -11.39 million, -54.27% less than in 2024.

Financial Statements

News

There is no news available yet.